Physician profile
Mark Real
NPI 1316332430
$583.13
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $25.61 · 2021: $91.20 · 2022: $29.06 · 2024: $35.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $35.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $35.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $288.38 | 2019-2021 | |
| Pfizer INC. | $121.35 | 2019 | |
| Abbvie INC. | $82.23 | 2019-2022 | |
| Boston Scientific Corporation | $35.84 | 2024 | |
| Celgene Corporation | $21.54 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.25 | 2019 | |
| Genzyme Corporation | $15.54 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Real listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.